Novo Nordisk submitted a BLA to the Food and Drug Administration for denecimig for the treatment of hemophilia A in September 2025.
Prophylactic cardiac treatment in DMD patients is associated with a 54% lower hazard of death, highlighting its potential survival benefit. Only 27.7% of DMD patients received prophylactic cardiac ...
Despite combination prophylaxis with HBIG and NUCs transforming outcomes after liver transplantation for hepatitis B, some ...
Bleeding prophylaxis with the investigational factor VIIIa mimetic bispecific antibody Mim8 (denecimig) was superior to ...
ASH and ISTH sought to develop clinical practice guidelines on anticoagulant prophylaxis for pediatric patients who are at risk of VTE.
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in ...
The COCOON trial assessed prophylactic dermatologic regimens in NSCLC patients treated with amivantamab and lazertinib, showing reduced AEs and improved quality of life. Prophylactic treatment ...
The introduction of urate-lowering therapy can affect the risk for gout flares, with fewer flares observed when less intensive treatment and flare prophylaxis were used. The introduction of ...
The RCTs included in this review have assessed a broad range of treatments that resulted in limited opportunities to describe and pool useful data. Studies available for analysis are a highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results